Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Spain · Delayed Price · Currency is EUR 61.50
+0.70 (1.15%)
Aug 27, 2026, 5:35 PM CET
BME:ROVI Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 773.05 | 743.48 | 763.75 | 829.51 | 817.7 | 648.68 | |
Revenue Growth | 3.21% | -2.65% | -7.93% | 1.44% | 26.06% | 54.46% |
Cost of Revenue | 272.63 | 271.9 | 296.04 | 346.17 | 305.27 | 268.84 |
Gross Profit | 500.42 | 471.59 | 467.71 | 483.34 | 512.43 | 379.84 |
Selling, General & Admin | 175.32 | 160.47 | 158.26 | 147.02 | 129.99 | 103.36 |
Other Operating Expenses | 140.65 | 107.6 | 102.73 | 92.52 | 105.84 | 74.96 |
Operating Expenses | 349.57 | 298.45 | 289.01 | 263.87 | 258.69 | 199.68 |
Operating Income | 150.85 | 173.14 | 178.71 | 219.47 | 253.74 | 180.15 |
Interest Expense | -3.99 | -2.56 | -1.99 | -0.95 | -0.85 | -0.91 |
Interest & Investment Income | 0.68 | 0.51 | 0.03 | 0.01 | 0.01 | 0.07 |
Earnings From Equity Investments | 0.22 | 0.06 | -0.14 | -0.13 | 0.2 | 0.18 |
Currency Exchange Gain (Loss) | -0 | -0.21 | 0.3 | -0.09 | -0.82 | -0.18 |
Other Non Operating Income (Expenses) | 25.11 | 12.33 | 0.79 | 2.09 | 3.93 | 3.4 |
EBT Excluding Unusual Items | 172.86 | 183.26 | 177.69 | 220.41 | 256.21 | 182.72 |
Gain (Loss) on Sale of Investments | - | - | - | - | 1.76 | - |
Asset Writedown | - | - | - | - | -0 | -0.1 |
Other Unusual Items | 62.35 | - | - | - | - | - |
Pretax Income | 235.21 | 183.26 | 177.69 | 220.41 | 257.97 | 182.63 |
Income Tax Expense | 50.17 | 42.9 | 40.81 | 50.11 | 58.3 | 29.55 |
Earnings From Continuing Operations | 185.04 | 140.36 | 136.88 | 170.3 | 199.67 | 153.08 |
Minority Interest in Earnings | 0.14 | 0.08 | 0.01 | 0.04 | 0 | - |
Net Income | 185.18 | 140.44 | 136.88 | 170.34 | 199.67 | 153.08 |
Net Income to Common | 185.18 | 140.44 | 136.88 | 170.34 | 199.67 | 153.08 |
Net Income Growth | 40.00% | 2.60% | -19.64% | -14.69% | 30.44% | 150.71% |
Shares Outstanding (Basic) | 51 | 51 | 51 | 53 | 53 | 55 |
Shares Outstanding (Diluted) | 51 | 51 | 51 | 53 | 53 | 55 |
Shares Change | 0.05% | -0.13% | -3.73% | -0.51% | -3.50% | 0.03% |
EPS (Basic) | 3.62 | 2.75 | 2.67 | 3.20 | 3.73 | 2.76 |
EPS (Diluted) | 3.62 | 2.75 | 2.67 | 3.20 | 3.73 | 2.76 |
EPS Growth | 39.93% | 2.73% | -16.53% | -14.25% | 35.31% | 150.36% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 179.39 | 121.87 | 79.16 | 59.45 | 186.88 | 109.22 |
Free Cash Flow Per Share | 3.51 | 2.38 | 1.55 | 1.12 | 3.50 | 1.97 |
Dividend Per Share | 0.959 | 0.959 | 0.935 | 1.104 | 1.294 | 0.956 |
Dividend Growth | 2.60% | 2.60% | -15.28% | -14.69% | 35.39% | 150.68% |
Gross Margin | 64.73% | 63.43% | 61.24% | 58.27% | 62.67% | 58.55% |
Operating Margin | 19.51% | 23.29% | 23.40% | 26.46% | 31.03% | 27.77% |
Profit Margin | 23.96% | 18.89% | 17.92% | 20.53% | 24.42% | 23.60% |
Free Cash Flow Margin | 23.21% | 16.39% | 10.37% | 7.17% | 22.86% | 16.84% |
EBITDA | 175.97 | 195.54 | 199.62 | 238.02 | 271.33 | 196.56 |
EBITDA Margin | 22.76% | 26.30% | 26.14% | 28.69% | 33.18% | 30.30% |
D&A For EBITDA | 25.12 | 22.39 | 20.91 | 18.54 | 17.59 | 16.41 |
EBIT | 150.85 | 173.14 | 178.71 | 219.47 | 253.74 | 180.15 |
EBIT Margin | 19.51% | 23.29% | 23.40% | 26.46% | 31.03% | 27.77% |
Effective Tax Rate | 21.33% | 23.41% | 22.97% | 22.73% | 22.60% | 16.18% |
Advertising Expenses | - | 18 | 21.74 | 21.75 | 19.99 | 12.71 |